公开(公告)号：US20220273617A1

公开(公告)日：2022-09-01

申请号：US17676684

申请日：2022-02-21

申请人： Ying Huang ,  Bradley Tram Andresen ,  Jinghua Jeffrey Wang ,  Vijay Kumar Nekkanti ,  Ayaz Shahid

发明人： Ying Huang ,  Bradley Tram Andresen ,  Jinghua Jeffrey Wang ,  Vijay Kumar Nekkanti ,  Ayaz Shahid

IPC分类号： A61K31/403 ,  A61P9/10 ,  A61P9/12 ,  A61P9/04 ,  A61P35/00

摘要： A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the β-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a β-blocker, with a highly potent antagonizing activity against the β-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-β-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation.

公开(公告)号：US20110177161A1

公开(公告)日：2011-07-21

申请号：US12601357

申请日：2008-05-27

申请人： Vijay Kumar Nekkanti ,  Pradeep Jairao Karatgi ,  Mahesh Paithankar ,  Raviraj Sukumar Pillai ,  Akella Venkateswarlu ,  Alikunju Shanvas ,  Reka Ajay Kumar ,  Mullangi Ramesh ,  Sirisilla Raju ,  Duvvuri Subrahmanyam ,  Rajagopal Sriram

发明人： Vijay Kumar Nekkanti ,  Pradeep Jairao Karatgi ,  Mahesh Paithankar ,  Raviraj Sukumar Pillai ,  Akella Venkateswarlu ,  Alikunju Shanvas ,  Reka Ajay Kumar ,  Mullangi Ramesh ,  Sirisilla Raju ,  Duvvuri Subrahmanyam ,  Rajagopal Sriram

IPC分类号： A61K31/437 ,  A61K9/48 ,  A61P35/00 ,  A61B19/00

CPC分类号： A61K9/0019 ,  A61K9/19 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0015 ,  C08L5/16

摘要： There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2′-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2′-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2′-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2′-hydroxyethoxy)-20(S)-CPT.

摘要翻译： 提供了用于药物产品的粉末组合物，该组合物包括a）5）（S） - （2'-羟基乙氧基）-20（S）-CPT; 至少一种环糊精; 其中5（S） - （2'-羟基乙氧基）-20（S）-CPT包括小于5（R） - （2'-羟基乙氧基）-20（S）-CPT的5％。 优选地，在粉末组合物中，5（S） - （2'-羟基乙氧基）-20（S）-CPT基本上不含所述5（R） - （2'-羟基乙氧基）-20（S）-CPT。